Skip to main content

Published locations for T2D patients on combination therapy benefit in switch from sitagliptin to liraglutide

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. T2D patients on combination therapy benefit in switch from sitagliptin to liraglutide

User login

  • Reset your password
  • /content/t2d-patients-combination-therapy-benefit-switch-sitagliptin-liraglutide
  • /familypracticenews/article/107951/diabetes/t2d-patients-combination-therapy-benefit-switch
  • /internalmedicinenews/article/107951/diabetes/t2d-patients-combination-therapy-benefit-switch
  • /clinicalendocrinologynews/article/107951/diabetes/t2d-patients-combination-therapy-benefit-switch
  • /diabeteshub/article/107951/diabetes/t2d-patients-combination-therapy-benefit-switch-sitagliptin
  • /endocrinology/article/107951/diabetes/t2d-patients-combination-therapy-benefit-switch-sitagliptin
  • /internalmedicine/article/107951/diabetes/t2d-patients-combination-therapy-benefit-switch-sitagliptin
  • /familymedicine/article/107951/diabetes/t2d-patients-combination-therapy-benefit-switch-sitagliptin
  • /type-2-diabetes-icymi/article/107951/diabetes/t2d-patients-combination-therapy-benefit-switch